Hospital
ST Francis Community Hospital
ST Francis Community Hospital was paid $44.77M by Medicaid between Jan 2018 and Dec 2024, across 325 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoST FRANCIS COMMUNITY HOSPITAL
FEDERAL WAY, WA 98003
FEDERAL WAY, WA 98003
33aNPI1093713091assigned 07/13/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.77M
24GClaims1,350,592
24DCodes billed325
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#12 of 49
Median peer was paid$20.06M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 223,226 | $7.59M | |
| 2019 | 219,740 | $7.63M | |
| 2020 | 185,974 | $6.10M | |
| 2021 | 198,599 | $6.26M | |
| 2022 | 191,865 | $6.39M | |
| 2023 | 189,237 | $6.02M | |
| 2024incomplete | 141,951 | $4.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 45,713 | 42,730 | $4.97M |
| 96361 | Intravenous infusion, hydration; each additional hour | 10% | 15,742 | 13,050 | $4.56M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 9.6% | 12,419 | 11,782 | $4.28M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 45,737 | 41,743 | $4.00M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 6.5% | 8,321 | 7,858 | $2.90M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 5.8% | 7,181 | 6,736 | $2.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 24,824 | 22,717 | $2.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 9,974 | 9,499 | $1.61M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 3.5% | 3,415 | 3,318 | $1.57M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 9,456 | 8,874 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 12,875 | 12,175 | $1.16M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 4,702 | 3,054 | $1.04M |
313 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 9,194 | $863K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 12,221 | $579K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 25,438 | $574K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 4,173 | $541K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 2,969 | $459K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,102 | $427K |
| 76830 | Ultrasound, transvaginal | <1% | 4,989 | $425K |
| 43248 | <1% | 1,155 | $383K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,628 | $383K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14,905 | $324K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,234 | $272K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,365 | $258K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,942 | $246K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,142 | $243K |
| G0378 | Hospital observation service, per hour | <1% | 7,719 | $234K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 692 | $229K |
| 95806 | <1% | 555 | $224K | |
| 76642 | <1% | 3,077 | $220K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,536 | $217K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,140 | $199K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 13,028 | $197K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,408 | $196K |
| 97161 | <1% | 4,628 | $184K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,164 | $181K |
| 12001 | <1% | 858 | $179K | |
| 10060 | <1% | 871 | $179K | |
| 76801 | <1% | 3,281 | $172K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,447 | $162K |
| 70496 | <1% | 1,166 | $158K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,386 | $156K |
| 76536 | <1% | 1,741 | $143K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 813 | $143K |
| 76770 | <1% | 1,516 | $130K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 863 | $115K |
| 43235 | <1% | 272 | $105K | |
| 84484 | <1% | 24,002 | $101K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,756 | $97K |
| 93971 | <1% | 1,189 | $92K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 579 | $89K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,321 | $86K |
| 80053 | Comprehensive metabolic panel | <1% | 20,677 | $85K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,714 | $83K |
| 29125 | <1% | 407 | $82K | |
| 93017 | <1% | 926 | $69K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,409 | $67K |
| 72100 | <1% | 3,540 | $62K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 425 | $61K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,168 | $61K |
| 12011 | <1% | 254 | $59K | |
| 77412 | <1% | 113 | $59K | |
| 73630 | <1% | 3,875 | $58K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,214 | $55K |
| 87040 | <1% | 8,579 | $54K | |
| 80076 | <1% | 19,510 | $51K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 133 | $51K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 456 | $48K |
| 80047 | <1% | 7,359 | $47K | |
| 73560 | <1% | 3,880 | $45K | |
| 73610 | <1% | 3,471 | $45K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,779 | $45K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,683 | $44K |
| 73030 | <1% | 3,351 | $43K | |
| 71250 | <1% | 956 | $41K | |
| 83605 | <1% | 7,948 | $41K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,422 | $39K |
| 96367 | <1% | 806 | $38K | |
| 97162 | <1% | 967 | $37K | |
| 70491 | <1% | 344 | $37K | |
| 73130 | <1% | 2,946 | $36K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,882 | $33K |
| 70486 | <1% | 773 | $32K | |
| 43249 | <1% | 191 | $32K | |
| 90715 | <1% | 1,832 | $31K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,189 | $31K |
| 72040 | <1% | 1,613 | $31K | |
| 74018 | <1% | 2,767 | $31K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,119 | $30K |
| 73110 | <1% | 2,282 | $29K | |
| 97035 | <1% | 4,329 | $28K | |
| 73502 | <1% | 2,293 | $27K | |
| 70498 | <1% | 1,062 | $26K | |
| 76870 | <1% | 277 | $25K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 207 | $24K |
| 83880 | <1% | 6,093 | $24K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,552 | $24K |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 165 | $22K |
| 84145 | <1% | 2,499 | $22K | |
| 85379 | <1% | 4,069 | $21K | |
| 76882 | <1% | 258 | $20K | |
| 45381 | <1% | 67 | $20K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,792 | $19K |
| 97165 | <1% | 527 | $18K | |
| 73140 | <1% | 1,120 | $18K | |
| 73562 | <1% | 821 | $18K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 286 | $17K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 40 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 13,561 | $16K |
| 19083 | <1% | 19 | $14K | |
| 12002 | <1% | 74 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 29,836 | $13K |
| 97116 | <1% | 1,178 | $13K | |
| 97113 | <1% | 287 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 23,355 | $12K |
| 72141 | <1% | 90 | $12K | |
| 93970 | <1% | 129 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,710 | $10K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,824 | $10K |
| 95819 | <1% | 96 | $10K | |
| 73590 | <1% | 1,239 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 42 | $9K |
| 77080 | <1% | 162 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 34,896 | $8K |
| 93458 | <1% | 12 | $8K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 54 | $8K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 118 | $8K |
| 91200 | <1% | 98 | $8K | |
| 74246 | <1% | 103 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 24,498 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,897 | $7K |
| 80143 | <1% | 1,899 | $7K | |
| 95811 | <1% | 26 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $6K |
| 71101 | <1% | 444 | $6K | |
| 29515 | <1% | 26 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,503 | $6K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $6K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 12 | $5K |
| 91010 | <1% | 14 | $5K | |
| 84702 | <1% | 7,332 | $5K | |
| 73090 | <1% | 756 | $5K | |
| 45330 | <1% | 15 | $5K | |
| 72131 | <1% | 161 | $5K | |
| 83690 | <1% | 21,942 | $5K | |
| 83735 | <1% | 5,575 | $4K | |
| 82962 | <1% | 16,296 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,485 | $4K |
| 87641 | <1% | 373 | $4K | |
| 73221 | <1% | 26 | $4K | |
| 73070 | <1% | 519 | $4K | |
| 36430 | <1% | 96 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 26,879 | $4K |
| 71271 | <1% | 49 | $4K | |
| 80179 | <1% | 1,835 | $4K | |
| 81001 | <1% | 25,245 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,567 | $3K |
| 96376 | <1% | 9,831 | $3K | |
| 59025 | Fetal non-stress test | <1% | 18 | $3K |
| 85610 | <1% | 20,015 | $3K | |
| 80061 | Lipid panel | <1% | 1,016 | $3K |
| 82565 | <1% | 8,964 | $3K | |
| 86850 | <1% | 2,316 | $2K | |
| 80051 | <1% | 7,278 | $2K | |
| 86900 | <1% | 3,158 | $2K | |
| 84703 | <1% | 7,207 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 53 | $2K |
| 76937 | <1% | 188 | $2K | |
| 86923 | <1% | 171 | $2K | |
| 90686 | <1% | 189 | $2K | |
| 73080 | <1% | 96 | $2K | |
| 81025 | <1% | 11,225 | $2K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 442 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 23,145 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,487 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,434 | $1K |
| 64450 | <1% | 13 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 7,899 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,522 | $1K |
| 85027 | <1% | 1,799 | $1K | |
| 84100 | <1% | 2,965 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,909 | $1K |
| 87070 | <1% | 3,836 | $1K | |
| 73060 | <1% | 80 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,724 | $1K |
| 82330 | <1% | 8,857 | $1K | |
| 86901 | <1% | 3,380 | $1K | |
| 96368 | <1% | 43 | $1K | |
| 88307 | <1% | 51 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,879 | $979.19 |
| 82803 | <1% | 1,038 | $899.05 | |
| 87205 | <1% | 3,653 | $858.47 | |
| 84112 | <1% | 147 | $857.96 | |
| 81003 | <1% | 8,360 | $820.38 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 115 | $803.14 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,883 | $801.52 |
| 87430 | <1% | 2,635 | $768.01 | |
| 70360 | <1% | 66 | $754.29 | |
| 72070 | <1% | 53 | $720.73 | |
| 73564 | <1% | 33 | $685.40 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 51 | $685.40 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,086 | $663.63 |
| 87186 | <1% | 3,792 | $662.44 | |
| 94060 | <1% | 13 | $574.26 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,055 | $539.87 |
| 82553 | <1% | 107 | $525.84 | |
| 82075 | <1% | 676 | $498.20 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 167 | $470.23 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 808 | $451.20 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,734 | $450.36 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,739 | $446.72 |
| 86140 | <1% | 1,178 | $446.65 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,384 | $438.88 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 72 | $433.79 |
| 82947 | <1% | 7,112 | $410.97 | |
| 85014 | <1% | 906 | $388.86 | |
| G0008 | Administration of influenza virus vaccine | <1% | 176 | $381.18 |
| J3490 | Unclassified drugs | <1% | 181 | $378.81 |
| 73620 | <1% | 27 | $374.52 | |
| 0240U | <1% | 1,291 | $360.26 | |
| 74019 | <1% | 40 | $357.84 | |
| 87077 | <1% | 1,956 | $341.31 | |
| 99152 | <1% | 1,305 | $326.14 | |
| 73660 | <1% | 28 | $316.17 | |
| 94729 | <1% | 12 | $310.73 | |
| 87808 | <1% | 1,443 | $287.12 | |
| 88342 | <1% | 2,524 | $280.08 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 713 | $251.16 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,511 | $241.33 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,911 | $233.48 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,913 | $232.00 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 32 | $229.85 |
| 88304 | <1% | 907 | $207.06 | |
| 87807 | <1% | 519 | $200.03 | |
| 82550 | <1% | 678 | $199.73 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,293 | $195.26 |
| A9270 | Non-covered item or service | <1% | 27,596 | $170.31 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,361 | $160.66 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,067 | $152.37 |
| 80050 | General health panel | <1% | 105 | $152.33 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,500 | $146.81 |
| 85651 | <1% | 792 | $142.76 | |
| 85018 | <1% | 577 | $138.81 | |
| 72170 | <1% | 27 | $136.54 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,407 | $104.05 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 697 | $103.24 |
| 84132 | <1% | 214 | $96.13 | |
| C1769 | Guide wire | <1% | 1,885 | $89.35 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 529 | $87.70 |
| 51702 | <1% | 72 | $85.69 | |
| 82270 | <1% | 313 | $76.52 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,753 | $75.11 |
| 82010 | <1% | 203 | $74.06 | |
| 81002 | <1% | 797 | $72.74 | |
| 87428 | <1% | 35 | $63.59 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,574 | $58.35 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 335 | $58.27 |
| 85730 | <1% | 815 | $56.28 | |
| 51798 | <1% | 38 | $52.86 | |
| 87147 | <1% | 460 | $49.68 | |
| 83540 | <1% | 68 | $44.35 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,507 | $40.01 |
| 83550 | <1% | 54 | $37.27 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,711 | $37.01 |
| 83615 | <1% | 119 | $33.46 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 466 | $31.08 |
| 84550 | <1% | 89 | $25.87 | |
| 82728 | <1% | 41 | $24.97 | |
| 84156 | <1% | 28 | $24.84 | |
| 73552 | <1% | 26 | $19.54 | |
| 85049 | <1% | 19 | $17.32 | |
| 82570 | <1% | 12 | $16.60 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 271 | $15.51 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 369 | $15.51 |
| 88341 | <1% | 230 | $14.69 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 836 | $14.59 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,075 | $10.47 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 318 | $8.21 |
| 0352U | <1% | 297 | $7.17 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 771 | $6.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 2,859 | $5.41 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,139 | $5.15 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,306 | $5.04 |
| 84450 | <1% | 13 | $3.78 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 263 | $3.24 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 445 | $1.55 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 78 | $1.45 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,608 | $1.37 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 383 | $0.62 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,124 | $0.03 |
| J1815 | Injection, insulin, per 5 units | <1% | 793 | $0.02 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 427 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 629 | $0.00 |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 76 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 517 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 25 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 210 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 116 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 165 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 421 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 139 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 94 | $0.00 |
| C1729 | Catheter, drainage | 0% | 73 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 59 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 16 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 77 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 106 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 26 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 69 | $0.00 |
| 51701 | 0% | 12 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 376 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 78 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 283 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 776 | $0.00 |
| 81015 | 0% | 39 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 108 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 211 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 354 | $0.00 |
| J1921 | Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg | 0% | 27 | $0.00 |
| 0099U | 0% | 41 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 18 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 354 | $0.00 |
| 36416 | 0% | 40 | $0.00 | |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPATEL, KETUL (CEO)